Sepracor and GlaxoSmithKline entered an agreement for the commercialization of Sepracor’s eszopiclone product for all markets outside the U.S., Canada, Mexico and Japan. Sepracor’s eszopiclone, known as Lunesta in the U.S., will be marketed by GSK in these areas as Lunivia for the treatment of insomnia. Under the agreement, Sepracor is entitled to receive an initial payment of $20 million plus success-based milestones totaling $155 million. Sepracor will also receive royalties based ...